Among patients with poly-refractory myeloma, autologous chimeric antigen receptor T-cell therapy offers exceptional promise. With the availability of bispecific antibodies, a total immunotherapeutic strategy in combination with chimeric antigen receptor T-cell therapy is now feasible.

See related article by Fandrei et al., p. 38

©2024 American Association for Cancer Research
2024
American Association for Cancer Research
You do not currently have access to this content.